Vita Life Sciences Projects H1 Sales of $46.3m-$47.3m with Stable Profit

Sales Growth Tempered by China Regulatory Headwinds

Vita Life Sciences (ASX:VLS) expects its revenue for the first half of 2026 to rise modestly to between $46.3 million and $47.3 million, up from $45.5 million in the same period last year. The company attributes this growth primarily to solid demand in its established Australian and Malaysia/Singapore markets. However, this positive momentum is partially offset by lower export volumes to China, where a shifting regulatory landscape and changing channel dynamics have disrupted sales.

Profit Guidance Reflects Cost Discipline and Earnings Quality

Pre-tax profit is forecasted to hold steady or edge slightly higher, ranging between $6.8 million and $7.3 million, compared to $6.8 million in H1 2025. Vita Life Sciences highlights ongoing cost discipline and the underlying quality of its earnings as key factors supporting profitability despite tougher economic conditions. This suggests the company is managing margin pressures effectively even as external challenges persist.

Robust Balance Sheet Supports Strategic Investment

The group maintains a strong financial footing, with substantial cash reserves and no borrowings. Its continued cash generation provides a buffer to fund ongoing investments aligned with its long-term strategic priorities. This financial resilience is notable given the uncertainties in the China market and broader economic headwinds.

Long-Term Growth Commitment Amid Market Shifts

Managing Director Andrew O’Keefe reaffirmed the company’s focus on sustainable long-term growth and shareholder value. While the China export market remains a challenge, Vita Life Sciences is leveraging its core markets to maintain steady progress. The company’s guidance reflects a cautious but stable outlook, balancing growth opportunities with the realities of a complex regulatory environment.